The Use of Atropine 0.01% in the Prevention and Control of Myopia (ATOM3)

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

300

Participants

Timeline

Start Date

April 21, 2017

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions

Myopia

Interventions

DRUG

Atropine sulfate 0.01%

Atropine 0.01%

DRUG

Placebo

placebo

Trial Locations (1)

Singapore eye research institute, Singapore

All Listed Sponsors

collaborator

National Medical Research Council (NMRC), Singapore

OTHER_GOV

lead

Singapore National Eye Centre

OTHER_GOV

NCT03140358 - The Use of Atropine 0.01% in the Prevention and Control of Myopia (ATOM3) | Biotech Hunter | Biotech Hunter